PDF Cover

Trihexyphenidyl Market

The market for Trihexyphenidyl was estimated at $205 million in 2024; it is anticipated to increase to $280 million by 2030, with projections indicating growth to around $362 million by 2035.

Report ID:DS1802020
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Trihexyphenidyl
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Trihexyphenidyl Market Outlook

Revenue, 2024

$205M

Forecast, 2034

$344M

CAGR, 2025 - 2034

5.3%

The Trihexyphenidyl industry revenue is expected to be around $216.2 million in 2025 and expected to showcase growth with 5.3% CAGR between 2025 and 2034. The Trihexyphenidyl market continues to gain strength because movement disorders are becoming more common and doctors keep using anticholinergic therapy in their practice. The established position of Trihexyphenidyl tablets in Parkinson's disease treatment pathways supports their demand while generic pharmaceuticals become more accessible through hospital pharmacies and retail channels. The Trihexyphenidyl market will continue to be important in the movement disorder drugs sector because doctors mainly use this medication for neurology and psychiatry patients and the population ages while more people receive diagnoses.

The anticholinergic medication Trihexyphenidyl serves as a long-established treatment for Parkinson's Disease and Extrapyramidal Symptoms which together make up 97.4% of its market presence. The tablet form of Trihexyphenidyl maintains its market leadership because it provides flexible dosing options and simple administration for patients who need long-term treatment. The drug maintains steady market demand because it provides effective tremor management and works as a Parkinson's disease treatment when used with levodopa and other medications while showing established safety benefits for properly chosen patients. The drug maintains its position as a fundamental treatment for Parkinson's disease because generic Trihexyphenidyl formulations continue to enter the market and emerging countries gain access to the medication while healthcare providers adjust treatment plans to control antipsychotic-induced extrapyramidal symptoms.

Trihexyphenidyl market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Trihexyphenidyl Market Outlook

Market Key Insights

  • The Trihexyphenidyl market is projected to grow from $205.3 million in 2024 to $344 million in 2034. This represents a CAGR of 5.3%, reflecting rising demand across Parkinson's Disease Management, Drug-induced Movement Disorders, and Off-label Usage in Dystonia.

  • The market competition stems from three major companies which include Pfizer Inc. and Teva Pharmaceutical Industries and Viatris Inc.

  • The Trihexyphenidyl market shows its highest demand through U.S. and Germany markets which will experience 3.4% to 5.1% annual growth rates from 2024 to 2030.

  • The research predicts Brazil, Indonesia and South Africa will experience the fastest market expansion at rates between 6.1% and 7.3% CAGR.

  • The Telemedicine transition creates expanding market potential for Trihexyphenidyl companies to promote their complete product range to healthcare providers. The Trihexyphenidyl product sales will increase by $3 million during 2025 because of the ecosystem pull-through effect.

  • The Trihexyphenidyl market will experience $139 million growth during 2024-2034 while Extrapyramidal Symptoms & Others Application will dominate market share expansion.

  • The market for Trihexyphenidyl will experience a 68% growth from 2024 to 2034 because of increasing parkinsons disease cases and shifting elderly population numbers.

trihexyphenidyl market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Trihexyphenidyl - Country Share Analysis

Opportunities in the Trihexyphenidyl

The absence of treatment for Parkinson’s disease and dystonia and other movement disorders in Latin America and the Middle East and Africa creates a major opportunity for Trihexyphenidyl market expansion. The local generic manufacturing sector together with distribution networks should work to deliver budget-friendly Trihexyphenidyl tablets which match current oral neurology treatment guidelines. The growing healthcare coverage and essential medicine lists will also drive up demand for affordable movement disorder treatments which will make Trihexyphenidyl tablets the leading volume driver while oral solutions will serve only specific tertiary medical facilities.

Growth Opportunities in North America and Asia-Pacific

The North American Trihexyphenidyl market depends on Parkinson's disease treatment because established clinical guidelines and wide neurologist adoption continue to drive demand while hospital and community psychiatry settings use the drug to treat antipsychotic-induced extrapyramidal symptoms. The main business opportunities exist in developing unique oral medication forms and fixed-dose combinations and patient adherence systems which focus on elderly patients and patients with prolonged movement disorders who receive preferential treatment from payers for evidence-based anticholinergic therapy and generic cost-effective formulations. The neurology market requires suppliers to maintain their market share through formulary placement and pharmacovigilance data and real-world treatment outcome evidence. The market receives support from three main factors which include high Parkinsonian syndrome diagnosis rates and complete insurance coverage for CNS disorders and ongoing antipsychotic prescriptions that maintain a consistent requirement for extrapyramidal symptom treatment.
The Asian-Pacific region experiences Trihexyphenidyl market growth because patients need treatment for extrapyramidal symptoms and limited access to Parkinson's disease medications which creates a dual-market structure. The market requires three main strategies to achieve success which include generic formulation distribution to secondary cities and medical education about movement disorder medication usage and product development for local prescribing habits and payment systems. The competitive market environment requires manufacturers to maintain cost leadership and deliver consistent quality and meet regulatory standards for sustained market success. The market demand for Trihexyphenidyl grows because of three main factors which include aging population expansion and increasing movement disorder diagnoses and better neuropsychiatric treatment availability and government programs that back essential chronic CNS medication access.

Market Dynamics and Supply Chain

01

Driver: Rising Parkinson’s Disease Burden Coupled With Growing Use in Drug-Induced Extrapyramidal Symptom Management

The trihexyphenidyl market is also expanding due to two interconnected yet distinct growth forces. First, the rising global prevalence of Parkinson’s disease driven by ageing populations and increased diagnostic precision is also creating sustained demand for effective anticholinergic therapies, particularly in regions where access to advanced dopaminergic drugs remains uneven. This is also also supported by improved clinical pathways emphasizing adjunctive treatment options. Second, growing recognition of trihexyphenidyl’s value in managing drug-induced extrapyramidal symptoms, especially those linked to antipsychotic and certain antidepressant regimens, continues to boost clinical utilization. Modern psychiatric practice trends, such as increased use of high-potency antipsychotics in resource-limited settings and broader monitoring protocols for neurological side effects, further reinforce the need for supportive medications like trihexyphenidyl. These combined factors drive significant and sustained growth momentum.
A key driver for the trihexyphenidyl market is also the rising preference for affordable anticholinergic therapies in low- and middle-income healthcare systems. As many regions continue to face budget constraints and limited access to newer neurological or psychiatric therapeutics, trihexyphenidyl remains a preferred option due to its low cost, established safety profile, and widespread availability in generic form. This trend is also further strengthened by infrastructural gaps that make advanced Parkinson’s disease treatments less accessible, prompting clinicians to rely on economical agents that offer symptomatic relief. The push for essential-medicine-based prescribing frameworks in developing nations also supports its continued adoption.
02

Restraint: Side effect profile and tolerability concerns restrict broader clinical usage

Trihexyphenidyl’s anticholinergic side effects, such as dry mouth, blurred vision, cognitive impairment, and urinary retention, significantly limit its use, especially in elderly Parkinson’s patients who are more vulnerable to these adverse reactions. Clinicians often prefer newer alternatives with better tolerability profiles, reducing prescriptions and market demand. For example, cognitive side effects may lead neurologists to avoid trihexyphenidyl in older populations, suppressing sales. These tolerability issues limit patient compliance, reduce long-term therapy adherence, and ultimately constrain overall market growth compared to better-tolerated movement disorder medications.
03

Opportunity: Trihexyphenidyl tablet use is expanding for Parkinson’s disease management among rapidly aging Asia–Pacific populations and Psychiatric hospitals increasingly adopt Trihexyphenidyl oral solutions to manage antipsychotic-induced extrapyramidal symptoms in elderly patients

The increasing number of Parkinson’s disease patients and earlier detection of the condition in Asia–Pacific regions create market demand for established antiparkinsonian medications including Trihexyphenidyl. Medical facilities that treat neurology patients and hospital pharmacies choose Trihexyphenidyl tablets because they offer flexible dosing options and affordable generic versions and established knowledge in movement disorder treatment. The global tablet market achieved $173.97 million in 2024 and experts predict it will reach $234.48 million by 2030 at a 5.1% annual growth rate. The market opportunity for Trihexyphenidyl tablets used in Parkinson’s disease adjunctive therapy will exceed oral solutions in both sales volume and market value.
The growing adoption of high-potency antipsychotics creates a rising need for reliable extrapyramidal symptoms treatment which makes Trihexyphenidyl an essential addition to psychiatric care. The oral solution format allows healthcare providers to adjust medication levels exactly for elderly patients who have swallowing difficulties which results in better treatment compliance in hospital and long-term care settings. The worldwide market for Trihexyphenidyl oral solutions reached $31.38 million in 2024 and experts predict it will expand to $45.46 million by 2030 at a 6.38% annual growth rate which makes it the fastest-growing Trihexyphenidyl formulation segment worldwide.
04

Challenge: Increasing availability of alternative therapies weakens trihexyphenidyl market position

The rise of newer pharmacologic agents for Parkinson’s disease management and drug-induced movement disorders, such as extended-release levodopa formulations, dopamine agonists, and botulinum toxin for focal dystonia, has reduced reliance on trihexyphenidyl. These alternatives often provide more effective symptom control with fewer anticholinergic effects, influencing prescriber preference and shifting demand away from older drugs. For instance, neurologists may choose second-generation therapies for extrapyramidal symptoms, lowering trihexyphenidyl prescriptions. This competitive landscape compresses market share, slows revenue growth, and shifts investment toward innovative therapies.

Supply Chain Landscape

1

Trihexyphenidyl API

Sun Pharmaceutical Industries Ltd.Intas Pharmaceuticals Ltd
2

Formulation Manufacturing

Pfizer Inc.Teva Pharmaceutical Industries Ltd.Viatris Inc
3

Pharma Distribution

McKesson CorporationCardinal Health Inc.AmerisourceBergen Corporation
4

Parkinson’s Treatment

Neurology ClinicsHospitalsRetail Pharmacies
Trihexyphenidyl - Supply Chain

Use Cases of Trihexyphenidyl in Parkinson's Disease Management & Drug-induced Movement Disorders

Parkinson's Disease Management : Trihexyphenidyl is primarily used in Parkinson’s disease management as an oral anticholinergic medication, most commonly prescribed in tablet form for ambulatory patients under neurologist supervision. It works by blocking central muscarinic receptors, helping to restore the imbalance between dopamine and acetylcholine in the basal ganglia. This mechanism is particularly effective in reducing tremors and rigidity, especially in younger patients with tremor dominant Parkinson’s disease. It is often used as adjunct therapy alongside levodopa to enhance symptomatic control. Its oral administration and affordability make it accessible in both hospital and outpatient neurology settings, particularly in cost sensitive healthcare systems.
Drug-induced Movement Disorders : Trihexyphenidyl is widely prescribed for managing drug induced movement disorders such as extrapyramidal symptoms caused by antipsychotic medications. In psychiatric and general hospital settings, oral tablets are the most common formulation, allowing flexible dose titration based on symptom severity. By counteracting cholinergic overactivity in the central nervous system, the drug effectively reduces dystonia, akathisia, and parkinsonian side effects associated with dopamine blocking agents. Its rapid onset of symptom relief makes it valuable in acute care scenarios. The relatively low cost and established clinical familiarity further support its routine use in psychiatry and neurology practices.
Off-label Usage in Dystonia : In dystonia, trihexyphenidyl is frequently used off label, particularly in pediatric and young adult patients with generalized or focal dystonia. Oral formulations are typically administered in gradually increasing doses to balance therapeutic benefit with tolerability. The drug helps reduce involuntary muscle contractions by modulating central cholinergic pathways involved in motor control. Although not universally effective, it remains one of the first line oral pharmacologic options before more invasive interventions such as botulinum toxin injections or deep brain stimulation are considered. Its accessibility and non invasive administration support continued demand in specialized movement disorder clinics.

Recent Developments

Recent developments in the trihexyphenidyl market reflect cautious prescribing driven by safety concerns and evolving therapeutic preferences. Prescribers are increasingly favoring newer antiparkinsonian agents and tailored regimens with improved tolerability, which has moderated demand for older anticholinergic drugs in movement disorder treatment. A key market trend is the shift toward personalized medicine and combination therapy strategies that balance symptom control with cognitive safety, especially in elderly Parkinson’s patients. As a result, clinical guidelines are refining trihexyphenidyl’s role, emphasizing its use in specific subgroups rather than broad first-line application.

December 2024 : Acme Pharmaceuticals has just unveiled their new formula for trihexyphenidyl with a focus, on enhancing the drug delivery system.
October 2024 : NeoMedic Inc revealed a commitment to advancing research and development in the realm of extended release trihexyphenidyl tablets with a primary focus on improving patient adherence, to treatment protocols.
August 2024 : BioCrux Ltd obtained patents for their technology involving dissolvable tablets of trihexyphenidyl which could lead to improved treatment options, for Parkinsons disease.

Impact of Industry Transitions on the Trihexyphenidyl Market

As a core segment of the Pharmaceutical industry, the Trihexyphenidyl market develops in line with broader industry shifts. Over recent years, transitions such as Shift Toward Precision Neurology and Cost-Driven Therapy Consolidation have redefined priorities across the Pharmaceutical sector, influencing how the Trihexyphenidyl market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Shift Toward Precision Neurology

The Trihexyphenidyl market is poised for significant growth as the industry transitions towards precision neurology, leveraging advanced diagnostic tools like wearable sensors and AI-driven gait analysis. This evolution enables clinicians to make more informed treatment decisions, optimizing the use of anticholinergics as adjunct therapies. Concurrently, the rise of telemedicine is expanding market opportunities, allowing Trihexyphenidyl companies to effectively promote their full product range to healthcare providers. This strategic shift is projected to drive an increase in product sales by $3 million in 2025, underscoring the ecosystem pull-through effect that enhances both patient outcomes and pharmaceutical profitability. As manufacturers refine formulations and delivery mechanisms to align with individualized care pathways, the Trihexyphenidyl market is set to capitalize on these transformative trends.
02

Cost-Driven Therapy Consolidation

A second key transition lies in the increasing consolidation of cost-efficient neurological therapy choices across emerging markets. Healthcare systems in Southeast Asia, Latin America, and parts of Africa are adopting essential-medicine formularies that streamline drug selection, placing long-used generics like trihexyphenidyl at the center of Parkinsonism and EPS management. This shift directly affects hospital procurement chains and regional generic-drug manufacturers, who are scaling production lines to meet rising volume requirements. It also pressures premium neurological drug developers to differentiate through advanced formulations, patient-support programs, or value-based reimbursement models.